CytoMed Therapeutics chairman reports 25.17% stake

His reported position includes shares issued in exchange for capital contributions, alongside directly held and entity-held shares.

Rhea-AI Filing Summary

CytoMed Therapeutics Ltd (GDTC) Chairman and Director Choo Chee Kong reported purchasing 29,250 ordinary shares in open-market transactions on the Nasdaq Capital Market between October 12, 2026 and October 15, 2026. The purchases had a weighted average price of $0.8587 per share and an aggregate purchase price of approximately $25,117.35, paid through his brokerage account with personal funds.

Choo reported beneficial ownership of 3,003,996 ordinary shares, representing 25.17% of CytoMed’s outstanding shares. The reported total includes 2,075,310 shares held indirectly through Glorious Finance Limited, 194,112 held by EP Capital Inc., and 734,574 held directly. Choo owns a 55% stake in Glorious Finance and disclaims beneficial ownership of the remainder of its 3,773,291-share holding. The amendment says Choo and Glorious Finance’s remaining shareholders may be deemed to act as a group because they share voting and dispositive power over those shares, without a formal agreement governing voting or investment decisions.

Filing Explained

Schedule 13D discloses ownership above 5% when a holder may seek to influence control; in this amendment, Choo says he has no current plan or proposal regarding the listed corporate actions, except as stated in the filing, though he may be asked to discuss or vote on them as a director.

Key Figures

Ordinary shares purchased: 29,250 shares Weighted average purchase price: $0.8587 per share Aggregate purchase price: Approximately $25,117.35 +5 more

8 metrics

Ordinary shares purchased 29,250 shares Open-market purchases between October 12, 2026 and October 15, 2026

Weighted average purchase price $0.8587 per share Open-market purchases between October 12, 2026 and October 15, 2026

Aggregate purchase price Approximately $25,117.35 Purchases between October 12, 2026 and October 15, 2026

Beneficial ownership 3,003,996 ordinary shares Reported by Choo Chee Kong

Percentage of outstanding shares 25.17% Choo Chee Kong’s reported beneficial ownership

Shares held indirectly through Glorious Finance Limited 2,075,310 ordinary shares Included in Choo Chee Kong’s reported beneficial ownership

Shares held by EP Capital Inc. 194,112 ordinary shares Included in Choo Chee Kong’s reported beneficial ownership

Shares held directly 734,574 ordinary shares Held directly by Choo Chee Kong

Key Terms

beneficial ownership, shared voting and dispositive power, acting as a "group" under Section 13(d)(3), weighted average price

4 terms

beneficial ownership regulatory

"beneficially owns 3,003,996 Ordinary Shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

shared voting and dispositive power regulatory

"shared voting and dispositive power over the 3,773,291 Ordinary Shares"

acting as a "group" under Section 13(d)(3) regulatory

"may be deemed to be acting as a "group" under Section 13(d)(3)"

weighted average price financial

"at a weighted average price of $0.8587 per share"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GDTC shares did Choo Chee Kong purchase, and at what price?

Choo Chee Kong reported purchasing 29,250 ordinary shares in open-market transactions on the Nasdaq Capital Market between October 12, 2026 and October 15, 2026, at a weighted average price of $0.8587 per share and an aggregate purchase price of approximately $25,117.35.

How many GDTC shares does Choo Chee Kong beneficially own?

Choo reported beneficial ownership of 3,003,996 ordinary shares, representing 25.17% of CytoMed’s outstanding shares. The reported total includes 2,075,310 shares held indirectly through Glorious Finance Limited, 194,112 held by EP Capital Inc., and 734,574 held directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/16/2026 - 06:06 AM EDT Accepted by SEC EDGAR 10/16/2026 - 06:05 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

CytoMed Therapeutics Ltd

(Name of Issuer)

Ordinary Shares

(Title of Class of Securities)

Y1R80M106

(CUSIP Number)

Choo Chee Kong
#08-22 ONE COMMONWEALTH,, 1 COMMONWEALTH LANE
Singapore, U0, 149544
65 6250 7738

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/12/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): Y1R80M106

1

Name of reporting person

Choo Chee Kong

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

SINGAPORE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 928,686.00
8	Shared Voting Power 3,773,291.00
9	Sole Dispositive Power 928,686.00
10	Shared Dispositive Power 3,773,291.00

11

Aggregate amount beneficially owned by each reporting person

3,003,996.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

25.17 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares
(b)	Name of Issuer: CytoMed Therapeutics Ltd
(c)	Address of Issuer's Principal Executive Offices: #08-22 ONE COMMONWEALTH, 1 COMMONWEALTH LANE, Singapore, SINGAPORE , 149544.
Item 2.	Identity and Background
(a)	Choo Chee Kong
(b)	1 Commonwealth Lane #08-22, Singapore 149544
(c)	The Reporting Person is the Chairman of the Board and Director of the Issuer. The address of the Issuer is 1 Commonwealth Lane #08-22, Singapore 149544
(d)	No
(e)	No
(f)	Singapore
Item 3.	Source and Amount of Funds or Other Consideration
	PF; Between October 12, 2026 and October 15, 2026, the Reporting Person acquired an aggregate of 29,250 Ordinary Shares in open market purchases on the Nasdaq Capital Market for an aggregate purchase price of approximately $25,117.35, settled through the Reporting Person's brokerage account with personal funds.
Item 4.	Purpose of Transaction
	Mr. Choo Chee Kong has acquired all of the Ordinary Shares beneficially owned by him (1) in exchange for capital contributions to the Issuer or (2) through public purchases on the open market with his personal funds for investment purposes. The Reporting Person serves as Chairman of the Issuer and is a member of the board of directors of the Issuer and, as a result, may be asked to vote on or discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others. Except as may be set forth herein, the Reporting Person has no current intention, plan or proposal with respect to items (a) through (j) of Item 4 of Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: the Reporting Person beneficially owns 3,003,996 Ordinary Shares, representing 25.17% of the Issuer's outstanding shares as of the date hereof. This includes: (1) 2,075,310 Ordinary Shares held indirectly through Glorious Finance Limited ("Glorious Finance"), in which Mr. Choo Chee Kong owns a 55% stake. As such, he is deemed to beneficially own 55% of the 3,773,291 shares held by Glorious Finance, while disclaiming ownership of the remainder. These shares were issued in exchange for capital contributions; (2) 194,112 Ordinary Shares held by EP Capital Inc. ("EP Capital"), which Mr. Choo Chee Kong is deemed to beneficially own. These shares were issued in exchange for capital contributions; and (3) 734,574 Ordinary Shares held directly by Mr. Choo Chee Kong, acquired with personal funds. The calculation is based on 11,934,908 Ordinary Shares outstanding as of the date hereof.
(b)	Please refer to Items 7-13 of the Cover Page. The Reporting Person has sole voting and dispositive power over 928,686 Ordinary Shares, and shared voting and dispositive power over 3,773,291 Ordinary Shares.
(c)	Between October 12, 2026 and October 15, 2026, the Reporting Person acquired an aggregate of 29,250 Ordinary Shares of the Issuer in open market purchases on the Nasdaq Capital Market, effected through a brokerage account, at a weighted average price of $0.8587 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Ordinary Shares purchased at each separate price. All such transactions were conducted in compliance with the Issuer's insider trading policy and Rule 10b-5 under the Securities Exchange Act of 1934, as amended.
(d)	None
(e)	N/A
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The Reporting Person and the remaining shareholders of Glorious Finance Limited may be deemed to be acting as a "group" under Section 13(d)(3) as they share voting and dispositive power over the 3,773,291 Ordinary Shares of the Issuer. However, there is no formal agreement governing their voting or investment decisions. Except as set forth herein, the Reporting Person has no contracts, arrangements, understandings, or relationships with respect to the Issuer's securities requiring disclosure under this Item 6.
Item 7.	Material to be Filed as Exhibits.
	Except as set forth herein, there are no material agreements, contracts, arrangements, or understandings that require filing as exhibits under this Item 7.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Choo Chee Kong

Signature:	/s/ Choo Chee Kong
Name/Title:	Choo Chee Kong / Chairman and Director of CytoMed Therapeutics Limited
Date:	10/16/2026